The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study
Diabetes & Metabolism Journal · 2023
DOI: 10.4093/dmj.2023.0171 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes & Metabolism Journal, 2023. Verfasst von Jun Sung Moon und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea. Hauptthemen laut MEDLINE: Anticholesteremic Agents, Hypercholesterolemia, Diabetes Mellitus, Type 2, Cardiovascular Diseases. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Yuhan Co. Ltd..
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
To investigate the efficacy and safety of moderate-intensity rosuvastatin/ezetimibe combination compared to highintensity rosuvastatin in high atherosclerotic cardiovascular disease (ASCVD) risk patients with type 2 diabetes mellitus (T2DM).
Methods
This study was a randomized, multicenter, open, parallel phase 4 study, and enrolled T2DM subjects with an estimated 10-year ASCVD risk ≥7.5%. The primary endpoint was the low-density lipoprotein cholesterol (LDL-C) change rate after 24-week rosuvastatin 10 mg/ezetimibe 10 mg treatment was non-inferior to that of rosuvastatin 20 mg. The achievement proportion of 10-year ASCVD risk
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
- Department of Internal Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
- Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.
- Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Korea.
Förderung
- Yuhan Co. Ltd.
Zitieren
APA
Moon, J. S., Park, I. R., Kim, S. S., Kim, H. S., Kim, N. H., Kim, S. G., Ko, S. H., Lee, J. H., Lee, I., Lee, B. K., & Won, K. C. (2023). The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study. Diabetes & Metabolism Journal. https://doi.org/10.4093/dmj.2023.0171
Vancouver
Moon JS, Park IR, Kim SS, Kim HS, Kim NH, Kim SG, et al. The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study. Diabetes & Metabolism Journal. 2023. doi:10.4093/dmj.2023.0171
BibTeX
@article{Moon2023,
author = {Moon, Jun Sung and Park, Il Rae and Kim, Sang Soo and Kim, Hye Soon and Kim, Nam Hoon and Kim, Sin Gon and Ko, Seung Hyun and Lee, Ji Hyun and Lee, Inkyu and Lee, Bo Kyeong and Won, Kyu Chang},
title = {The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study},
journal = {Diabetes & Metabolism Journal},
year = {2023},
doi = {10.4093/dmj.2023.0171}
}
EUVIMED